Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know?
Serena Maria BocciaCarolina Maria SassuRaffaella ErgastiLaura VertechyAdriana Ionelia ApostolEleonora PalluzziAnna FagottiGiovanni ScambiaClaudia MarchettiPublished in: Drug design, development and therapy (2024)
In the era of single and combination maintenance therapies as well as platinum and Poly (ADP-ribose) polymerase inhibitors (PARPi) resistance, the choice of subsequent treatments following first-line platinum-based chemotherapy in recurrent ovarian cancer (ROC) patients has become increasingly complex. Within the ovarian cancer treatment algorithm, particularly in the emerging context of PARPi resistance, the role of trabectedin, in combination with pegylated liposomal doxorubicin (PLD) still preserves its significance. This paper offers valuable insights into the multifaceted role and mechanism of action of trabectedin in ROC. The main results of clinical trials and studies involving trabectedin/PLD, along with hints of Breast Cancer genes (BRCA)-mutated and BRCAness phenotype cases, are critically discussed. Moreover, this review provides and contextualizes potential scenarios of administering trabectedin in combination with PLD in ROC, according to established guidelines and beyond.
Keyphrases
- clinical trial
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- ejection fraction
- machine learning
- drug delivery
- deep learning
- randomized controlled trial
- squamous cell carcinoma
- cancer therapy
- patient reported outcomes
- gene expression
- risk assessment
- study protocol
- transcription factor
- rectal cancer
- phase ii
- bioinformatics analysis